Treatment Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery
Cancer pain can be associated with the cancer itself or with conventional cancer treatments such as chemotherapy or surgery, and it affects over 3 million people in the US alone. Currently, there is a vast range of drugs used in the treatment of cancer pain including opioids, Nsaids, antidepressants and anticonvulsants, yet most physicians consider morphine to be the current gold standard.
Scope of Report:
- Key data and detailed analysis of the 7 leading pharmaceutical markets: the US, Japan, Germany, France, Italy, Spain, and the UK
- In-depth analysis of presentation rates, diagnosis and referral patterns of cancer pain
- Detailed examination of first, second and third line therapies for the treatment of mild, moderate and severe cancer pain
- Investigation of the treatment of breakthrough pain
Report Highlights
- Cancer pain affects over three million people in the US alone, yet despite the availability of a wide range of analgesics and published treatment guidelines, many patients still receive inadequate pain management
- Increased education and awareness of cancer pain and its management among physicians and patients is of critical importance in improving treatment outcomes
Reasons to Purchase
- Identify commercial opportunities from an understanding of the prevalence of cancer pain in the seven major pharmaceutical markets
- Exploit the opportunity to play a pivotal role in promoting effective pain management by providing increased patient and physician education
- Identify first, second and third-line preferred therapies for cancer pain, and the novel non-invasive formulations of breakthrough pain analgesics
Table of Contents
DRIVERS AND TRENDS
Cancer pain can be associated with the cancer itself or with conventional cancer treatments such as chemotherapy or surgery, and it affects over 3 million people in the US alone. Despite the publication of numerous treatment guidelines, many patients still experience pain as a result of inadequate analgesia. Currently, there is a vast range of drugs used in the treatment of cancer pain including opioids, NSAIDs and adjuvant pain drugs such as antidepressants and anticonvulsants, and most physicians consider morphine to be the current gold standard.
COMPARATIVE ANALYSIS
Compares the prevalence, presentation, diagnosis and treatment rates of cancer pain across the seven countries studied. Presents physicians' preferred lines of drug treatment to highlight the potential opportunities in this market. The management of breakthrough cancer pain across the seven major markets is analyzed and Datamonitor proposes areas of opportunity for companies who are already in the cancer pain market and for those companies who are planning to planning to enter this exciting area of pain management:
- How does the prevalence rates of cancer pain vary across the major pharmaceutical markets?
- How common are multidisciplinary oncology teams in the seven markets?
- What methods are used to assess cancer pain severity?
- Are treatment guidelines widely used in each of the markets?
- What factors influence physicians' prescribing in cancer pain management?
- Do physicians' preferred first and second-line therapies differ from one market to another?
THE US MARKET
In-depth analysis of the epidemiology, presentation, diagnosis, and treatment rates of cancer pain in the US in 2002, presenting physicians' preferred first, second and third-line drug treatments:
- Why do only a small proportion of US physicians treating cancer pain use published treatment guidelines?
- Are multidisciplinary oncology teams involved in the treatment of cancer pain?
- Which drug class is most frequently used in the treatment of mild cancer pain?
- Which adjuvant drug classes are used in the treatment of moderate and severe cancer pain?
- Is morphine considered the gold standard in the treatment of breakthrough pain?
THE JAPANESE MARKET
In-depth analysis of the epidemiology, presentation, diagnosis, and treatment rates of cancer pain in Japan in 2002, presenting physicians' preferred first, second and third-line drug treatments:
- What proportion of Japanese cancer patients suffer from pain?
- What is the breakdown of cancer pain severity in Japan?
- What is the preferred first-line treatment of moderate cancer pain?
- What adjuvant pain drugs are used in the treatment of mild, moderate and severe cancer pain?
- What proportion of cancer pain patients experience breakthrough pain?
THE FRENCH MARKET
In-depth analysis of the epidemiology, presentation, diagnosis, and treatment rates of cancer pain in France in 2002, presenting physicians' preferred first, second and third-line drug treatments:
- What proportion of French physicians treating cancer pain use published treatment guidelines?
- Are multidisciplinary oncology teams involved in the treatment of cancer pain?
- Which drug class is most frequently used in the treatment of mild cancer pain?
- Which adjuvant drug classes are used in the treatment of mild, moderate and severe cancer pain?
THE GERMAN MARKET
In-depth analysis of the epidemiology, presentation, diagnosis, and treatment rates of cancer pain in Germany in 2002, presenting physicians' preferred first, second and third-line drug treatments:
- What proportion of cancer pain patients in Germany suffer from nociceptive, neuropathic and mixed nociceptive/neuropathic pain?
- Do physicians use published treatment guidelines?
- Are multidisciplinary oncology teams involved in the treatment of cancer pain?
- What are German physicians' preferred first- and secondline drug therapies to treat moderate and severe cancer pain?
- Which drug class is most frequently used in the treatment of mild cancer pain?
- What proportion of cancer pain patients in Germany suffer from breakthrough pain?
THE ITALIAN MARKET
In-depth analysis of the epidemiology, presentation, diagnosis, and treatment rates of cancer pain in Italy in 2002, presenting physicians' preferred first, second and third-line drug treatments:
- Why do interviewed physicians estimate that less than half of their cancer patients suffer from some form of cancer pain?
- What is the breakdown of cancer pain types in Italy?
- Are multidisciplinary oncology teams involved in the treatment of cancer pain?
- Why is ketorolac considered to be the treatment of choice for moderate cancer pain in Italy?
- Which adjuvant drug classes are used in the treatment of mild, moderate and severe cancer pain?
- What proportion of cancer patients use patient controlled analgesia in Italy?
THE SPANISH MARKET
In-depth analysis of the epidemiology, presentation, diagnosis, and treatment rates of cancer pain in Spain in 2002, presenting physicians' preferred first, second and third-line drug treatments:
- What proportion of cancer pain patients are treated for pain?
- What treatment guidelines do physicians follow to treat cancer pain?
- Which diagnostic tools do physicians utilize in Spain?
- Which drug classes are most frequently used in the treatment of mild, moderate and severe cancer pain?
- Are tricyclic antidepressants used as adjuvant pain drugs in the treatment of cancer pain?
- What drugs are used to treat breakthrough cancer pain?
THE UK MARKET
In-depth analysis of the epidemiology, presentation, diagnosis, and treatment rates of cancer pain in the UK in 2002, presenting physicians' preferred first, second and third-line drug treatments:
- Which physicians are involved in the treatment of cancer pain in the UK?
- How is cancer pain diagnosed and assessed?
- What are the treatment rates of cancer pain in the UK?
- Which drug class is most frequently used in the treatment of mild, moderate and severe cancer pain?
- Which adjuvant pain drug classes are used?
- What is the average daily dose of physicians' preferred first-line therapy for moderate and severe cancer pain in the UK?
- How is breakthrough cancer pain managed in the UK?
APPENDIX
Presents the full research methodology and the questionnaire used to determine physicians' opinions on the referral, assessment and treatment of cancer pain.
This In-Depth Analysis also includes 77 Data Tables and 184 Figures.
Other users found this report page using the following search terms: cancer pain pain pain cancer treatment breakthrough drug guidelines algorithm used management which
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.